BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30517658)

  • 21. Establishment and characterization of patient-derived xenograft of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion.
    Damayanti NP; Saadatzadeh MR; Dobrota E; Ordaz JD; Bailey BJ; Pandya PH; Bijangi-Vishehsaraei K; Shannon HE; Alfonso A; Coy K; Trowbridge M; Sinn AL; Zhang ZY; Gallagher RI; Wulfkuhle J; Petricoin E; Richardson AM; Marshall MS; Lion A; Ferguson MJ; Balsara KE; Pollok KE
    Sci Rep; 2023 Jun; 13(1):9163. PubMed ID: 37280243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained Response to the Mitogen-Activated Extracellular Kinase Inhibitor Trametinib in a Spindle Cell Sarcoma Harboring a QKI-RAF1 Gene Fusion.
    Panet F; Jung S; Alcindor T
    JCO Precis Oncol; 2022 Jan; 6():e2100303. PubMed ID: 35050712
    [No Abstract]   [Full Text] [Related]  

  • 23. Cerebellar Pleomorphic Xanthoastrocytoma with BRAF V600E Mutation.
    Kim SH; Hwang K; Lee KS; Choe G; Kim CY
    World Neurosurg; 2020 Jul; 139():577-581. PubMed ID: 32348888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation.
    Tanaka S; Nakada M; Nobusawa S; Suzuki SO; Sabit H; Miyashita K; Hayashi Y
    Brain Tumor Pathol; 2014 Jul; 31(3):172-6. PubMed ID: 24894018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spinal cord anaplastic astrocytoma with BRAF V600E mutation: A case report and review of literature.
    Takamiya S; Hatanaka KC; Ishi Y; Seki T; Yamaguchi S
    Neuropathology; 2020 Jun; 40(3):275-279. PubMed ID: 31986557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.
    Lohkamp LN; Schinz M; Gehlhaar C; Guse K; Thomale UW; Vajkoczy P; Heppner FL; Koch A
    PLoS One; 2016; 11(6):e0156422. PubMed ID: 27253461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
    Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
    Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma.
    Hicks JK; Henderson-Jackson E; Duggan J; Joyce DM; Brohl AS
    Diagn Pathol; 2018 Oct; 13(1):77. PubMed ID: 30314519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
    Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
    Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.
    Cin H; Meyer C; Herr R; Janzarik WG; Lambert S; Jones DT; Jacob K; Benner A; Witt H; Remke M; Bender S; Falkenstein F; Van Anh TN; Olbrich H; von Deimling A; Pekrun A; Kulozik AE; Gnekow A; Scheurlen W; Witt O; Omran H; Jabado N; Collins VP; Brummer T; Marschalek R; Lichter P; Korshunov A; Pfister SM
    Acta Neuropathol; 2011 Jun; 121(6):763-74. PubMed ID: 21424530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF V600E-mutated central nervous system tumor with divergent morphological feature - Anaplastic pleomorphic xanthoastrocytoma-like and astroblastoma-like.
    Purkait S; Bansal S; Malgulwar PB
    Neuropathology; 2019 Feb; 39(1):64-67. PubMed ID: 30557911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.
    Forshew T; Tatevossian RG; Lawson AR; Ma J; Neale G; Ogunkolade BW; Jones TA; Aarum J; Dalton J; Bailey S; Chaplin T; Carter RL; Gajjar A; Broniscer A; Young BD; Ellison DW; Sheer D
    J Pathol; 2009 Jun; 218(2):172-81. PubMed ID: 19373855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.
    Kaulich K; Blaschke B; Nümann A; von Deimling A; Wiestler OD; Weber RG; Reifenberger G
    J Neuropathol Exp Neurol; 2002 Dec; 61(12):1092-9. PubMed ID: 12484572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.
    Palanisamy N; Ateeq B; Kalyana-Sundaram S; Pflueger D; Ramnarayanan K; Shankar S; Han B; Cao Q; Cao X; Suleman K; Kumar-Sinha C; Dhanasekaran SM; Chen YB; Esgueva R; Banerjee S; LaFargue CJ; Siddiqui J; Demichelis F; Moeller P; Bismar TA; Kuefer R; Fullen DR; Johnson TM; Greenson JK; Giordano TJ; Tan P; Tomlins SA; Varambally S; Rubin MA; Maher CA; Chinnaiyan AM
    Nat Med; 2010 Jul; 16(7):793-8. PubMed ID: 20526349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring DNA Methylation for Prognosis and Analyzing the Tumor Microenvironment in Pleomorphic Xanthoastrocytoma.
    Tang K; Kurland D; Vasudevaraja V; Serrano J; Delorenzo M; Radmanesh A; Thomas C; Spino M; Gardner S; Allen JC; Nicolaides T; Osorio DS; Finlay JL; Boué DR; Snuderl M
    J Neuropathol Exp Neurol; 2020 Aug; 79(8):880-890. PubMed ID: 32594172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spinal pleomorphic xanthoastrocytoma companied with periventricular tumor.
    Zhao X; Jiang X; Wang X
    Int J Clin Exp Pathol; 2015; 8(1):1036-40. PubMed ID: 25755815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF V600E mutation: A treatable driver mutation in pleomorphic xanthoastrocytoma (PXA).
    Hofer S; Berthod G; Riklin C; Rushing E; Feilchenfeldt J
    Acta Oncol; 2016; 55(1):122-3. PubMed ID: 25811650
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations.
    Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H
    Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers.
    Rankin A; Johnson A; Roos A; Kannan G; Knipstein J; Britt N; Rosenzweig M; Haberberger J; Pavlick D; Severson E; Vergilio JA; Squillace R; Erlich R; Sathyan P; Cramer S; Kram D; Ross J; Miller V; Reddy P; Alexander B; Ali SM; Ramkissoon S
    Oncologist; 2021 Jan; 26(1):e153-e163. PubMed ID: 32918774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [BRAF V600E mutation and clinicopathologic characteristics in 250 cases of brain tumors associated with epilepsy].
    Qi XL; Yao K; Duan ZJ; Bian Y; Ma Z; Piao YS; Gong LP
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):664-670. PubMed ID: 30220118
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.